Brivaracetam

Drug Profile

Brivaracetam

Alternative Names: BRIVIACT; BRIVLERA; RIKELTA; UCB-34714

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator UCB
  • Class Antiepileptic drugs; Neuroprotectants; Non-opioid analgesics; Nootropics; Pyrrolidinones; Small molecules
  • Mechanism of Action Sodium channel antagonists; SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myoclonic epilepsies
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy
  • Discontinued Myoclonic epilepsies; Postherpetic neuralgia

Most Recent Events

  • 12 May 2017 Phase-II/III clinical trials in Epilepsy (In neonates) in Hungary (IV) (EudraCT2017-04-06)
  • 12 May 2017 Phase-II/III clinical trials in Epilepsy (In neonates) in Hungary (PO) (EudraCT2017-04-06)
  • 22 Apr 2017 Interim pharmacokinetics data from phase I trial (In volunteers) presented at the 69th Annual Meeting of the American Academy of Neurology ((AAN-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top